	US 12,134,661 B1
	Covalent multi-specific antibody
Zhenhao Zhou, Chengdu (CN); Jie Zhang, Chengdu (CN); and Xiaoqing Wang, Chengdu (CN)
Assigned to Chimagen Biosciences, Ltd., Sichuan (CN)
Filed by CHIMAGEN BIOSCIENCES, LTD., Sichuan (CN)
Filed on May 17, 2024, as Appl. No. 18/668,012.
Application 18/668,012 is a continuation of application No. 17/596,789, previously published as PCT/CN2020/087668, filed on Apr. 29, 2020.
Claims priority of application No. 201910535703.7 (CN), filed on Jun. 20, 2019.
Int. Cl. C07K 16/46 (2006.01)

CPC C07K 16/468 (2013.01) [C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/64 (2013.01)]

1 Claim

1. An engineered multi-specific antibody that bins to CD3, CD19 and CD20, and comprises:

(i) a first polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 10;

(ii) a second polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 11,

(iii) a third polypeptide comprising the amino acid sequence of set forth in SEQ ID NO: 12; and

(iv) a fourth polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 13.